Enolase 1 (ENO1) compositions and uses thereof
US11224641B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 28, 2018 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Nov 28, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/042
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.